1. Scrip

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

Pricing And Value Questions Dominate

 
• By Eleanor Malone and Joseph Haas

The US election will intensify  the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.

Scrip Perspectives 2019 to 2020

More than 80 industry executives have shared with Scrip their expectations for the year ahead. In the third part of our preview series, we put the spotlight on the policy and regulatory environment.

The US election in November was mentioned by many as a significant issue for the industry in 2020. “This is an election year of pivotal importance to our nation and to our industry,” Jeremy Levin, chairman of BIO and CEO of Ovid Therapeutics Inc., said

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Asks

More from Scrip

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’